NCT07064330View on ClinicalTrials.gov

Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

July 17, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Cutaneous Squamous Cell Carcinoma (CSCC)
Interventions
DRUG

Cemiplimab

350 mg IV every 3 weeks as per standard of care. Patients are observed prospectively for biomarkers of response and toxicity during cemiplimab treatment.

Trial Locations (1)

37007

RECRUITING

Complejo Asistencial Universitario de Salamanca, Salamanca

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

collaborator

Carlos III Health Institute

OTHER_GOV

collaborator

University of Salamanca

OTHER

lead

Instituto de Investigación Biomédica de Salamanca

OTHER

NCT07064330 - Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab. | Biotech Hunter | Biotech Hunter